APA

Syrjänen S., Naud P., Sarian L., Derchain S., Roteli-Martins C., Longatto-Filho A., Tatti S., Branca M., Erzen M., Hammes L. S., Costa S. & Syrjänen K. (20100217). Up-regulation of 14-3-3sigma (Stratifin) is associated with high-grade CIN and high-risk human papillomavirus (HPV) at baseline but does not predict outcomes of HR-HPV infections or incident CIN in the LAMS study. : American journal of clinical pathology.

Chicago

Syrjänen Stina, Naud Paulo, Sarian Luis, Derchain Sophie, Roteli-Martins Cecilia, Longatto-Filho Adhernar, Tatti Silvio, Branca Margerita, Erzen Mojca, Hammes Luciano S, Costa Silvano and Syrjänen Kari. 20100217. Up-regulation of 14-3-3sigma (Stratifin) is associated with high-grade CIN and high-risk human papillomavirus (HPV) at baseline but does not predict outcomes of HR-HPV infections or incident CIN in the LAMS study. : American journal of clinical pathology.

Harvard

Syrjänen S., Naud P., Sarian L., Derchain S., Roteli-Martins C., Longatto-Filho A., Tatti S., Branca M., Erzen M., Hammes L. S., Costa S. and Syrjänen K. (20100217). Up-regulation of 14-3-3sigma (Stratifin) is associated with high-grade CIN and high-risk human papillomavirus (HPV) at baseline but does not predict outcomes of HR-HPV infections or incident CIN in the LAMS study. : American journal of clinical pathology.

MLA

Syrjänen Stina, Naud Paulo, Sarian Luis, Derchain Sophie, Roteli-Martins Cecilia, Longatto-Filho Adhernar, Tatti Silvio, Branca Margerita, Erzen Mojca, Hammes Luciano S, Costa Silvano and Syrjänen Kari. Up-regulation of 14-3-3sigma (Stratifin) is associated with high-grade CIN and high-risk human papillomavirus (HPV) at baseline but does not predict outcomes of HR-HPV infections or incident CIN in the LAMS study. : American journal of clinical pathology. 20100217.